Cyclic compounds (1)
Mood stabilizers (1)
AK Scientific (1)
Oakwood Chemical (1)
Lurasidone (367514-88-3, 367514-87-2)
Lurasidone (trade name Latuda) is an atypical antipsychotic developed by Dainippon Sumitomo Pharma and marketed by Sunovion in the U.S. It has been an FDA approved treatment for schizophrenia since 2010 and for treating depressive episodes in adults with bipolar I disorder since 2013. It can be used alone or in combination with mood stabilizers such as lithium or valproate (e.g., Depakote).
STP (hallucinogen) (15588-95-1)
2,5-Dimethoxy-4-methylamphetamine (DOM; known on the street as STP, standing for "Serenity, Tranquility and Peace") is a psychedelic and a substituted amphetamine. It was first synthesized by Alexander Shulgin, and later reported in his book PiHKAL: A Chemical Love Story. DOM is classified as a Schedule I substance in the United States, and is similarly controlled in other parts of the world.
amisulpride (71675-85-9, 53583-79-2)
Solian · sultopride · DAN 2163
Amisulpride, sold under the brand name Solian among others, is an antipsychotic medication used to treat schizophrenia. In Italy, at a lower dosage of 50 mg per day, it is also used as a treatment for dysthymia. It is usually classed with the newer generation of antipsychotics, the so called atypical antipsychotics.
Agomelatine (brand names Valdoxan, Melitor, Thymanax) is an atypical antidepressant developed by the pharmaceutical company Servier. It is marketed for the treatment of major depressive disorder, primarily for its relatively favorable side effect profile: it avoids the weight gain, sexual dysfunction, and severe withdrawal associated with the most commonly used classes of antidepressants (SSRIs, SNRIs, tricyclics), while providing similar therapeutic benefit. Due to its distinctive mechanism of action, agomelatine is also studied for its effects on sleep regulation.
Nitoman · Orphan Brand of Tetrabenazine · Tetrabenazine Orphan Brand
Tetrabenazine is a drug for the symptomatic treatment of hyperkinetic movement disorders. It is marketed under the trade names Nitoman in Canada and Xenazine in New Zealand, some parts of Europe and in the United States as an orphan drug. On August 15, 2008, the U.S.
NORFENFLURAMINE (673-18-7, 1886-26-6)
Norfenfluramine, or 3-trifluoromethylamphetamine, is a never-marketed drug of the amphetamine family which behaves as a serotonin and norepinephrine releasing agent and potent 5-HT2A, 5-HT2B, and 5-HT2C agonist. The action of norfenfluramine on 5-HT2B receptors on heart valves leads to a characteristic pattern of heart failure following proliferation of cardiac fibroblasts on the tricuspid valve, known as cardiac fibrosis. This side effect led to the withdrawal of fenfluramine as an anorectic agent worldwide, and to the withdrawal of benfluorex in Europe, as both fenfluramine and benfluorex form norfenfluramine as an active metabolite.
MMDA (3-methoxy-4,5-methylenedioxyamphetamine; 5-methoxy-MDA) is a psychedelic and entactogen drug of the amphetamine class. It is an analogue of lophophine, MDA, and MDMA. MMDA was described by Alexander Shulgin in his book PiHKAL.
4-(4'-chlorophenyl)-4-piperidinol · 39512-49-7 · 4-(4-chlorophenyl)-4-hydroxypiperidine
Remoxipride (Roxiam) is an atypical antipsychotic (although according to some sources it is a typical antipsychotic) which was previously used in Europe for the treatment of schizophrenia and acute mania but was withdrawn due to toxicity concerns (incidence of aplastic anemia in 1/10,000 patients). It was initially launched by AstraZeneca in 1990 and suspension of its use began in 1993. Remoxipride acts as a selective D2 and D3 receptor antagonist and also has high affinity for the sigma receptor, possibly playing a role in its atypical neuroleptic action.
4-Fluoroamphetamine (4-FA; 4-FMP; PAL-303; "Flux"), also known as para-fluoroamphetamine (PFA) is a psychoactive research chemical of the phenethylamine and substituted amphetamine chemical classes. It produces stimulant and entactogenic effects, and is described subjectively as being between amphetamine and MDMA. As a recreational drug, 4-FA is sometimes sold along with related compounds such as 2-fluoroamphetamine and 4-fluoromethamphetamine.
Clozapine N-oxide (34233-69-7)
AMPHETAMINE (60-15-1, 300-62-9)
Amphetamine Sulfate · Levoamphetamine · Phenamine
Amphetamine (contracted from alpha-methylphenethylamine) is a potent central nervous system (CNS) stimulant that is used in the treatment of attention deficit hyperactivity disorder (ADHD), narcolepsy, and obesity. Amphetamine was discovered in 1887 and exists as two enantiomers: levoamphetamine and dextroamphetamine. Amphetamine properly refers to a specific chemical, the racemic free base, which is equal parts of the two enantiomers, levoamphetamine and dextroamphetamine, in their pure amine forms.
TMAs, also known as trimethoxyamphetamines, are a family of isomeric psychedelic hallucinogenic drugs. There exist six different TMAs that differ only in the position of the three methoxy groups: TMA, TMA-2, TMA-3, TMA-4, TMA-5, and TMA-6. The TMAs are analogs of the phenethylamine cactus alkaloid mescaline.
Butyrophenone is a chemical compound; some of its derivatives (called commonly butyrophenones) are used to treat various psychiatric disorders such as schizophrenia, as well as acting as antiemetics. Examples of butyrophenones include: Haloperidol, the most widely used classical antipsychotic drug in this class Benperidol, the most potent commonly used antipsychotic ( 200 times more potent than chlorpromazine)
2-phenethylamine · phenethylamine hydrobromide · phenethylamine sulfate (2:1)
Phenethylamine (PEA), also known as β-phenylethylamine (β-PEA) and 2-phenylethan-1-amine, is an organic compound, natural monoamine alkaloid, and trace amine which acts as a central nervous system stimulant in humans. Phenylethylamine functions as a monoaminergic neuromodulator and, to a lesser extent, a neurotransmitter in the human central nervous system. It is biosynthesized from the amino acid L-phenylalanine by enzymatic decarboxylation via the enzyme aromatic L-amino acid decarboxylase.
2,5-Dimethoxy-4-ethylamphetamine (DOET, DOE, Hecate) is a psychedelic drug of the phenethylamine and amphetamine chemical classes. It was first synthesized by Alexander Shulgin, and was described in his book PiHKAL (Phenethylamines i Have Known And Loved).